CN106138615A - A kind of medicine for treating myasthenia gravis - Google Patents
A kind of medicine for treating myasthenia gravis Download PDFInfo
- Publication number
- CN106138615A CN106138615A CN201610661151.0A CN201610661151A CN106138615A CN 106138615 A CN106138615 A CN 106138615A CN 201610661151 A CN201610661151 A CN 201610661151A CN 106138615 A CN106138615 A CN 106138615A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- myasthenia gravis
- kidney
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
Abstract
The present invention relates to a kind of medicine for treating myasthenia gravis, it is to be prepared from by the raw medicinal material of following weight proportion: Rhizoma Dioscoreae Nipponicae 7 parts, the Radix Astragali 1 part, the Rhizoma Atractylodis Macrocephalae 6 parts, Radix Salviae Plectranthoidis 7 parts, Fructus Lycii 12 parts, Semen Cuscutae 10 parts, Radix Rehmanniae 12 parts, 1 part of Folium Nelumbinis, the Cortex Eucommiae 2 parts.The present invention uses: Radix Rehmanniae nourishing kidney yin；The flat kidney-replenishing of Semen Cuscutae；Folium Nelumbinis sending up the lucid YANG；Fructus Lycii nourishing the liver and kidney；Radix Astragali benefiting QI and nourishing blood, flat the kidney invigorating gas；Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI；Radix Salviae Plectranthoidis qi-restoratives fills out marrow；Rhizoma Dioscoreae Nipponicae promoting blood circulation to remove obstruction in the collateral.All medicines share, and reach nourishing YIN for benefiting the kidney, the most flat kidney-replenishing, another nourishing the liver spleen invigorating, effect of replenishing and activating blood.Clinical trial certificate, the present invention can safely and effectively treat myasthenia gravis.
Description
Technical field
The present invention relates to a kind of Chinese medicine, be specifically related to a kind of medicine for treating myasthenia gravis.
Background technology
Myasthenia gravis (myasthenia gravis, MG) is a kind of by acetyl gallbladder on neuromuscular junction postsynaptic membrane
Alkali receptor (acetylcholine receptor, AchR) transmission autoimmune disease caused by dysfunction, is
One of common neuromuscular disease, is characterized so that the striped muscle got involved is unable.Clinic mainly shows as part or whole body skeleton
Myasthenia and fatiguability, exacerbation of symptoms after activity, through having a rest and cholinesterase inhibitor (cholinesterase
Inhibitors, ChEI) treatment after symptom alleviate.Sickness rate is 8～20/,100,000, and prevalence is 50/,100,000, women prevalence
More than male, about 3:2, each age group all has a morbidity, child 1～5 years old in the majority, south China sickness rate is higher.Myasthenia gravis
Patient often merge hyperthyroidism, thyroiditis, systemic lupus erythematosus (sle), rheumatoid arthritis and pemphigus etc. other
Autoimmune disease.Up to now, there is no specific short, its etiology and pathogenesis also imperfectly understands.At present, one is compared
The understanding caused, belongs to autoimmune disease.
The symptom of primary disease " sheath ", " flaccidity ", " blepharoptosis " contained with Chinese medical book, " ptosis ", " serious blepharoptosis " etc. are similar.
The cause of disease
The pathogenic factor of myasthenia gravis divides two big classes, and a class is inborn genetic, and Ji Shaojian is unrelated with autoimmune；Second
Class is autoimmune disease, most common.Pathogenic factor is still not clear, generally believe with infect, medicine, environmental factors relevant.
Having 65%～80% to have thymic hyperplasia in Patients With Myasthenia Gravis, 10%～20% occurs together thymoma simultaneously.
Clinical manifestation
Myasthenia gravis initial stage patient often feels eye or the limbs swollen discomfort of acid, or blurred vision, and easily tired, weather is scorching
Heat or tired during menstrual onset increase the weight of.Along with PD, the obvious fatigue and weak of skeletal muscle, distinguishing feature is that myasthenia is afternoon
Or fatigue postemphasis at dusk, alleviate after rising morning or having a rest, this kind of phenomenon referred to as " gently weight at dusk in morning ".
1. Patients With Myasthenia Gravis whole body skeletal muscle all can be got involved, and can have following symptom
1. droopy eyelids, blurred vision, diplopia, stravismus, Rotation of eyeball are dumb.
2. apathetic expression, risus sardonicus, speech lisper, dysarthria, often accompany rhinophonia.
3. masticatory atonia, drinking-water choke cough, dysphagia.
4. neck soft, come back difficulty, turn neck, shrug unable.
5. carry arm, comb one's hair, go upstairs, squat down, difficulty of getting on the bus.
2. Clinical typing
1. the Osseman typing improved
I type ocular type；Whole body type that IIA type is slight, extremity muscle group often accompanies eye muscle to get involved, without the performance of pseudobulbar paralysis, i.e. without nozzle
Chew and dysphagia dysarthria；IIB type extremity muscle group often accompanies eye muscle to get involved, and has the performance of pseudobulbar paralysis, how within half a year
Dyspnea occurs；How type III (the radical type of severe) morbidity rapidly, is developed into dyspnea by several weeks or several months；IV type is (tardy
Serious symptom type) how to develop by I type, IIA type, IIB type at about 2 years；V-type amyotrophy type, rare.
2. myasthenic crisis
Refer to that the state of an illness that Patients With Myasthenia Gravis occurs suddenly in the course of disease for a certain reason drastically deteriorates, dyspnea, danger
And the critical phenomenon of life.According to different reasons, MG crisis generally divides 3 types:
Myasthenic crisis is mostly caused by the development of disease itself.Also can because of infection, fatigue, direct stimulation, menstruation,
Childbirth, operation, wound and induce.Clinical manifestation is that the myasthenia symptom of patient increases the weight of suddenly, occurs swallowing unable with expectoration, exhales
Inhale difficulty, often accompany the symptoms such as dysphoria, dripping sweat.
Cholinergic crisis sees the patient of " pyridostigmine bromide " of long-term taking larger dose, or takes for the moment too much, sends out
Often first show before raw crisis Nausea and vomiting, suffer from abdominal pain, suffer from diarrhoea, hyperhidrosis, shed tears, skin is clammy, oral secretion increases, flesh
Bundle trembles and the mental symptom such as excited, anxiety.
The dosage of anti-stubborn crisis " pyridostigmine bromide " is unchanged, but loses efficacy this medicine suddenly and occurred in that serious breathing is stranded
Difficult.Also can be because infecting, caused by electrolyte disturbance or other unknown causes.
In above 3 kinds of crisis, myasthenic crisis is most common, is secondly anti-stubborn property crisis, and real cholinergic crisis is the most rare
See.
Drug therapy
1. cholinesterase inhibitor
Being the medicine of symptomatic treatment, cure the symptoms, not the disease, it is impossible to single medicine prolonged application, administrated method should be cumulative from low dose.Conventional
Have neostigmine methylsulfate, pyridostigmine bromide.
2. immunosuppressant
Conventional immunosuppressant is: Corticosteroid: prednisone, methyl meticortelone etc.；Azathioprine；Ring
Embrace element A；Cycli phosphate amine；Tacrolimus.
3. plasmapheresis
By the way of by acetylcholine receptor antibodies removal in blood samples of patients, the symptom of respite Patients With Myasthenia Gravis,
If do not assisted other treatment mode, curative effect is less than 2 months.
4. immunoglobulin'intravenous
Containing Multiple Antibodies in human immunoglobulin, autoantibody, regulation immunologic function can be neutralized.Its effect is put with blood plasma
Commutation is worked as.
5. Chinese medicine
The Chinese traditional treatment of myasthenia gravis increasingly comes into one's own.Myasthenia gravis belongs to " flaccidity " category.According to theory of Chinese medical science,
Add with Chinese medicine in treatment, it is possible to reduce the side effect that immunosuppressant is brought, the treatment of myasthenia gravis plays guarantor
Drive the effect of convoy, and effect of autoimmune function can be rebuild.
Medical material involved in the present invention all seen from be recorded in " China book on Chinese herbal medicine ".
Summary of the invention
It is desirable to provide a kind of medicine for treating myasthenia gravis, by selecting suitable medical material and joining
Ratio, reaches safely and effectively to cure the purpose of myasthenia gravis.
In order to achieve the above object, the present invention is by the following technical solutions:
A kind of medicine for treating myasthenia gravis, it is characterised in that it is to be prepared by the raw medicinal material of following weight proportion
Form: Rhizoma Dioscoreae Nipponicae 7 parts, the Radix Astragali 1 part, the Rhizoma Atractylodis Macrocephalae 6 parts, Radix Salviae Plectranthoidis 7 parts, Fructus Lycii 12 parts, Semen Cuscutae 10 parts, Radix Rehmanniae 12 parts, Folium Nelumbinis 1
Part, the Cortex Eucommiae 2 parts.
Illustrate the method have the benefit that below in conjunction with theories of Chinese materia medica
It has been recognised by the inventors that the morbidity of myasthenia gravis, how because of deficiency of kidney-essence, deficiency of liver-blood, deficiency of both YIN and YANG.Therefore YIN nourishing benefit is answered in treatment
Kidney, the most flat kidney-replenishing, another nourishing the liver spleen invigorating, replenishing and activating blood.
The present invention uses: Radix Rehmanniae nourishing kidney yin；The flat kidney-replenishing of Semen Cuscutae；Folium Nelumbinis sending up the lucid YANG；Fructus Lycii nourishing the liver and kidney；Yellow
Stilbene benefiting QI and nourishing blood, flat the kidney invigorating gas；Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI；Radix Salviae Plectranthoidis qi-restoratives fills out marrow；Rhizoma Dioscoreae Nipponicae promoting blood circulation to remove obstruction in the collateral.All medicines share, and reach
Nourishing YIN for benefiting the kidney, the most flat kidney-replenishing, another nourishing the liver spleen invigorating, effect of replenishing and activating blood.
Below in conjunction with clinical laboratory data beneficial effects of the present invention is described:
1, physical data
Inventor collects 109 example Patients With Myasthenia Gravis between in March ,-2015 in April, 2012 altogether.It is randomly divided into: treatment group 55 example,
Matched group 54 example.Male 34 examples of wherein treatment group, female 21 example, age 19～63 years old, the course of disease 1～23 years；Matched group man 32 examples, female 22
Example, between age 21～66 years old, the course of disease 1～21 years.The data such as two groups of sexes, age, courses of disease there was no significant difference, and has comparable
Property.
Diagnostic criteria
1. necessary requirement: have typical striped muscle unable and fatiguability performance, alleviate after rest, activity postemphasis, or under the morning is light
Noon weight, clinical manifestation is blepharoptosis, myasthenia of limbs, dysphagia even dyspnea.
2. reference conditions: neostigmine test is positive；Electromyography repetitive nerve stimulation is attenuation effect, or ultimate fibre flesh
Electrograph checks that Jitter(trembles) more than 55 μ s or retardances；The anti-acetylcholine receptor antibodies test positive；Breast CT or MR check
Can there be hypertrophy of thymus or thymus neoplasms.
All have one of above-mentioned necessary requirement and reference conditions item person, can be diagnosed as myasthenia gravis.
1. inclusive criteria meets diagnostic criteria；2. the age 18～70 years old；3. compliance is good；Sign informed consent the most voluntarily
Book.
Exclusion standard 1. gestation, women breast-feeding their children；2. suffer from severe cardiac, lung, liver, renal disease patient；3. spiritedness system
System disease, it is impossible to partner treatment person；4. through the patient of other drug treatment after morbidity.
2, Therapeutic Method
Treatment group is administered orally the capsule that the present invention prepares according to specific embodiment 3, three times a day.Treat 2 months.
Matched group is administered orally this bright of pyrrole, each 120mg, three times a day.Treat 2 months.
3, criterion of therapeutical effect and therapeutic outcome
3.1 criterion of therapeutical effect
1. recovery from illness: clinical symptoms, sign all disappear, resumes work or is engaged in light work electromyogram and recover normally or arbitrarily to shrink
Rear muscle action potential amplitude-frequency decrescence phenomenon is obvious, follows up a case by regular visits to 1 year without recurrence；
The most effective: clinical symptoms or sign make moderate progress, anti-acetylcholinesterase agent and hormone successively decrease more than 1/5, and electromyogram is slightly
There is improvement or unchanged；
The most invalid: unchanged before and after clinical symptoms, sign and drug dose treatment.
3.2 treatment statistical results are shown in Table 1.
1 liang of table group comparitive study
| Group | n | Recovery from illness | Effectively | Invalid | Total effective rate (%) | Obvious adverse reaction example |
| Treatment group | 55 | 23 | 26 | 6 | 89% | 0 |
| Matched group | 54 | 21 | 23 | 10 | 81% | 0 |
Visible, myasthenia gravis can safely and effectively be treated by the medicine that the present invention prepares, and cure rate is high.
Detailed description of the invention
In order to be more fully understood that and implement the present invention, further illustrate the present invention below in conjunction with specific embodiment.
Embodiment 1
Weigh: Rhizoma Dioscoreae Nipponicae 7 grams, the Radix Astragali 1 gram, the Rhizoma Atractylodis Macrocephalae 6 grams, Radix Salviae Plectranthoidis 7 grams, Fructus Lycii 12 grams, Semen Cuscutae 10 grams, Radix Rehmanniae 12 grams,
1 gram of Folium Nelumbinis, the Cortex Eucommiae 2 grams；Add 8 times amount water, decoct 1.5 hours, filter；Filtering residue adds 6 times amount water, decocts 1 hour, filters；Merge
Filtrate, is concentrated into 120 grams, must meet the decoct of one day consumption of adult normal.
For treating myasthenia gravis.Oral, the most once.
Embodiment 2
Weigh: Rhizoma Dioscoreae Nipponicae 7 grams, the Radix Astragali 1 gram, the Rhizoma Atractylodis Macrocephalae 6 grams, Radix Salviae Plectranthoidis 7 grams, Fructus Lycii 12 grams, Semen Cuscutae 10 grams, Radix Rehmanniae 12 grams,
1 gram of Folium Nelumbinis, the Cortex Eucommiae 2 grams；Add 10 times amount water, decoct 2 hours, filter；Filtering residue adds 8 times amount water, decocts 1.5 hours, filters；Merge
Filtrate, concentrates, and is dried, and packaging must meet the powder of one day consumption of adult normal.
For treating myasthenia gravis.Oral, every bu is taken for twice sooner or later.
Embodiment 3
Weigh: Rhizoma Dioscoreae Nipponicae 7 grams, the Radix Astragali 1 gram, the Rhizoma Atractylodis Macrocephalae 6 grams, Radix Salviae Plectranthoidis 7 grams, Fructus Lycii 12 grams, Semen Cuscutae 10 grams, Radix Rehmanniae 12 grams,
1 gram of Folium Nelumbinis, the Cortex Eucommiae 2 grams；Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentrate, be dried, load capsule
Shell, must meet the capsule of one day consumption of adult normal.
For treating myasthenia gravis.Oral, every bu morning, noon and afternoon take for three times.
Claims (4)
1. the medicine being used for treating myasthenia gravis, it is characterised in that it is by the raw medicinal material system of following weight proportion
For forming: Rhizoma Dioscoreae Nipponicae 7 parts, the Radix Astragali 1 part, the Rhizoma Atractylodis Macrocephalae 6 parts, Radix Salviae Plectranthoidis 7 parts, Fructus Lycii 12 parts, Semen Cuscutae 10 parts, Radix Rehmanniae 12 parts, lotus
1 part of leaf, the Cortex Eucommiae 2 parts.
2. the medicine for treating myasthenia gravis as claimed in claim 1, it is characterised in that its preparation method is: weigh:
Rhizoma Dioscoreae Nipponicae 7 parts, the Radix Astragali 1 part, the Rhizoma Atractylodis Macrocephalae 6 parts, Radix Salviae Plectranthoidis 7 parts, Fructus Lycii 12 parts, Semen Cuscutae 10 parts, Radix Rehmanniae 12 parts, 1 part of Folium Nelumbinis, Du
Secondary 2 parts；Add 8 times amount water, decoct 1.5 hours, filter；Filtering residue adds 6 times amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into
120 parts, obtain decoct；Above-mentioned part each means weight portion.
3. the medicine for treating myasthenia gravis as claimed in claim 1, it is characterised in that its preparation method is: weigh:
Rhizoma Dioscoreae Nipponicae 7 parts, the Radix Astragali 1 part, the Rhizoma Atractylodis Macrocephalae 6 parts, Radix Salviae Plectranthoidis 7 parts, Fructus Lycii 12 parts, Semen Cuscutae 10 parts, Radix Rehmanniae 12 parts, 1 part of Folium Nelumbinis, Du
Secondary 2 parts；Add 10 times amount water, decoct 2 hours, filter；Filtering residue adds 8 times amount water, decocts 1.5 hours, filters；Merging filtrate, concentrates,
It is dried, packaging, obtains powder；Above-mentioned part each means weight portion.
4. the medicine for treating myasthenia gravis as claimed in claim 1, it is characterised in that its preparation method is: weigh:
Rhizoma Dioscoreae Nipponicae 7 parts, the Radix Astragali 1 part, the Rhizoma Atractylodis Macrocephalae 6 parts, Radix Salviae Plectranthoidis 7 parts, Fructus Lycii 12 parts, Semen Cuscutae 10 parts, Radix Rehmanniae 12 parts, 1 part of Folium Nelumbinis, Du
Secondary 2 parts；Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentrate, be dried, load capsule shells, obtain glue
Wafer；Above-mentioned part each means weight portion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610661151.0A CN106138615A (en) | 2016-08-13 | 2016-08-13 | A kind of medicine for treating myasthenia gravis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610661151.0A CN106138615A (en) | 2016-08-13 | 2016-08-13 | A kind of medicine for treating myasthenia gravis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106138615A true CN106138615A (en) | 2016-11-23 |
Family
ID=57329695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610661151.0A Pending CN106138615A (en) | 2016-08-13 | 2016-08-13 | A kind of medicine for treating myasthenia gravis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138615A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111867401A (en) * | 2018-03-09 | 2020-10-30 | 科丝美诗奈斯株式会社 | Functional food composition comprising folium Nelumbinis extract for enhancing muscle function and athletic ability, and its preparation method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101352514A (en) * | 2008-05-04 | 2009-01-28 | 北京中科仁和科技有限公司 | Chinese medicinal composition for treating myasthenia gravis and preparation method thereof |
| CN102406798A (en) * | 2011-11-27 | 2012-04-11 | 鲍颖 | Chinese medicinal composition for treating myasthenia gravis |
| CN104984245A (en) * | 2015-07-10 | 2015-10-21 | 包莉丽 | Traditional Chinese medicine for treating gastroptosis |
-
2016
- 2016-08-13 CN CN201610661151.0A patent/CN106138615A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101352514A (en) * | 2008-05-04 | 2009-01-28 | 北京中科仁和科技有限公司 | Chinese medicinal composition for treating myasthenia gravis and preparation method thereof |
| CN102406798A (en) * | 2011-11-27 | 2012-04-11 | 鲍颖 | Chinese medicinal composition for treating myasthenia gravis |
| CN104984245A (en) * | 2015-07-10 | 2015-10-21 | 包莉丽 | Traditional Chinese medicine for treating gastroptosis |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111867401A (en) * | 2018-03-09 | 2020-10-30 | 科丝美诗奈斯株式会社 | Functional food composition comprising folium Nelumbinis extract for enhancing muscle function and athletic ability, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520618B (en) | A kind of pharmaceutical composition for the treatment of erection disturbance and preparation method thereof and pharmaceutical applications | |
| CN103933294B (en) | A kind of plant extract compositions for sexual dysfunction | |
| CN106728321A (en) | A kind of eye ointment and preparation method thereof | |
| CN101293073B (en) | Chinese medicinal composition for treating systematic lupus erythematosus | |
| CN106138615A (en) | A kind of medicine for treating myasthenia gravis | |
| CN103877376B (en) | A kind of pharmaceutical preparation treating depression | |
| CN101590114B (en) | Medicament for treating multiple sclerosis and preparation method thereof | |
| CN102743696A (en) | Preparation method of traditional Chinese medicine lotion for treating blood stasis type cellulitis | |
| CN106237268A (en) | One treats schizoid pharmaceutical composition and application thereof | |
| CN102335311A (en) | Decoction for treating intestinal obstruction, and application thereof | |
| CN102366588A (en) | Traditional Chinese medicine for treating nephritis | |
| CN102813757B (en) | Preparation method of traditional Chinese medicine for treating lumbago type acute glomerulonephritis | |
| CN104324135A (en) | Traditional Chinese medicine composition for treating ischemic stroke and preparation method and application of traditional Chinese medicine composition | |
| CN116173153B (en) | Traditional Chinese medicine composition and medicine for treating central nervous system inflammatory demyelinating diseases | |
| CN103800844B (en) | A kind of pharmaceutical composition for the treatment of acute pancreatitis and preparation method thereof | |
| CN103961391B (en) | A kind of pharmaceutical composition treating gastrointestinal neurosis | |
| CN112439037B (en) | Medicine for relieving fatigue syndrome | |
| CN102813771A (en) | Preparation method of traditional Chinese medicine for treating hydroncus type acute glomerulonephritis | |
| CN115737778B (en) | Traditional Chinese medicine preparation with pressure regulating effect | |
| CN102743698A (en) | Preparation method of traditional Chinese medicine lotion for treating pain type cellulitis | |
| CN105770417A (en) | Medicine for treating myasthenia gravis | |
| CN105853586A (en) | Medicine for treating myasthenia gravis and preparation method thereof | |
| CN104474173A (en) | Medicine for treating facial nerve paralysis | |
| CN102727618B (en) | Application of Caulis et Folium Hedyotis Hedyotideae in preparation of drug or health product for promoting lead removing | |
| CN104306912A (en) | Traditional Chinese medicine used for treating meniere disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161123 |